Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison to Study the Safety and Antimicrobial Efficacy of DBI-001 Gel Vs. Placebo

Next Previous
Trial Profile

A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison to Study the Safety and Antimicrobial Efficacy of DBI-001 Gel Vs. Placebo

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DBI 001 (Primary)
  • Indications Atopic dermatitis; Skin infections; Staphylococcal infections
  • Focus Adverse reactions
  • Sponsors DermBiont

Most Recent Events

  • 16 Jun 2021 Status changed from suspended to discontinued as Covid-19 has shut the clinic indefinitely.
  • 01 Feb 2021 Planned End Date changed from 30 Oct 2020 to 28 Feb 2021.
  • 01 Sep 2020 Planned End Date changed from 15 Aug 2020 to 30 Oct 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top